Advertisement

Annals of Surgical Oncology

, Volume 25, Issue 11, pp 3271–3279 | Cite as

Impact of Combination Chemotherapy in Peritoneal Mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The RENAPE Study

  • Brice Malgras
  • Etienne Gayat
  • Olivier Aoun
  • Réa Lo Dico
  • Clarisse Eveno
  • Karine Pautrat
  • Jean-Baptiste Delhorme
  • Guillaume Passot
  • Frédéric Marchal
  • Olivia Sgarbura
  • Gwenael Ferron
  • Diane Goéré
  • Thierry Andre
  • Marc Pocard
  • on behalf of the RENAPE Network
Gastrointestinal Oncology
First Online:
Received:
  • 176 Downloads

Abstract

Background

The introduction of cytoreductive surgery (CRS) in combination with hyperthermic intraperitoneal chemotherapy (HIPEC) improved the prognosis of selected patients with peritoneal mesothelioma (PM).

Objective

The objective of our study was to evaluate whether different HIPEC agents were associated with different outcomes in patients with PM.

Methods

From the RENAPE database, we selected all patients with histology-proven PM who underwent CRS + HIPEC from 1989 to 2014. Inclusion criteria were age ≤ 80 years, performance status ≤ 2, and no extraperitoneal metastases.

Results

Overall, 249 patients underwent CRS + HIPEC for PM. The HIPEC regimen included five chemotherapeutic agents (CAs), consisting of cisplatin, doxorubicin, mitomycin-C, oxaliplatin, and irinotecan. When considering all CAs (alone or in combination), there was no significant statistical difference in regard to postoperative overall survival (OS). However, OS was better when using two CAs (group 2 drugs) versus one CA (group 1 drug) (p = 0.03). The different CA regimens were equally distributed between the two groups. This association between OS and HIPEC agent, as well as a trend for better progression-free survival, were both observed in the two-drug group versus the one-drug group (p = 0.009) for patients undergoing complete cytoreductive surgery (CC-0) with an epithelioid subtype.

Conclusions

This large study seems to show improved OS when combined CAs, especially with platinum-based regimens, are used for HIPEC in patients with PM, but needs to be confirmed by a randomized controlled trial.

This is a preview of subscription content, log in to check access.

Notes

Acknowledgement

The members of the RENAPE Network organization include: Julio Abba, MD (Department of Digestive Surgery, Grenoble University Hospital, Grenoble, France); Karine Abboud, MD (Department of General Surgery, CHU Hospital, Jean Monnet University, Saint Étienne, France); Mohammad Alyami, MD (Department of Digestive Surgery, Lyon-Sud University Hospital, Lyon, France); Catherine Arvieux, MD, PhD (Department of Digestive Surgery, Grenoble University Hospital, Grenoble, France); Gerlinde Averous, MD (Department of Pathology, Hautepierre University Hospital, Strasbourg, France); Naoual Bakrin, MD, PhD (Department of Digestive Surgery, Lyon-Sud University Hospital, Lyon, France); Gisèle Balagué, MD (Department of Radiology, Claudius Regaud Institute IUTC, Toulouse, France); Vincent Barrau, MD (Department of Radiology, Centre Cardiologique du Nord, Saint Denis, France); Houda Ben Rejeb, MD (Department of Pathology, Bergonie Institute, Bordeaux, France); Jean-Marc Bereder, MD, PhD (Department of Digestive Surgery, Archet 2 University Hospital, Nice, France); Isabelle Berton-Rigaud (Department of Digestive Oncology, ICO René Gauducheau Cancer Center, Saint-Herblain, France); Frédéric Bibeau, MD, PhD (Department of Pathology, Caen University Hospital, Caen, France); Isabelle Bonnefoy (Department of Digestive Surgery, Lyon-Sud University Hospital, Lyon, France); Dominique Bouzard, MD, (Department of Surgery, Louis Mourier University Hospital, Colombes, France); Ivan Bricault, MD, PhD (Department of Radiology, Grenoble University Hospital, Grenoble, France); Cécile Brigand, MD, PhD (Department of Digestive Surgery, Hautepierre University Hospital, Strasbourg, France); Sébastien Carrère, MD (Department of Surgical Oncology, Val d’Aurelle Montpellier Cancer Center, Montpellier, France); Cécile de Chaisemartin, MD (Department of Surgical Oncology, Paoli Calmettes Institute, Marseille, France); Madleen Chassang, MD (Department of Radiology, Archet 2 University Hospital, Nice, France); Anne Chevallier, MD (Department of Pathology, Archet 2 University Hospital, Nice, France); Thomas Courvoisier, MD (Department of Digestive Surgery, Poitiers University Hospital, Poitiers, France); Peggy Dartigues, MD (Department of Pathology, Gustave Roussy Institute, Villejuif, France); Anthony Dohan, MD, PhD (Department of Radiology, Lariboisière University Hospital, Paris, France); Julien Dubreuil, MD, PhD (Department of Radiology, Lyon-Sud University Hospital, Lyon, France); Frédéric Dumont, MD (Department of Surgical Oncology, ICO René Gauducheau Cancer Center, Saint-Herblain, France); Clarisse Eveno, MD, PhD (Surgical Oncologic and Digestive Unit, Lariboisière University Hospital, Paris, France); Marie Faruch-Bilfeld, MD (Department of Radiology, University Hospital of Toulouse, Toulouse, France); Gwenaël Ferron, MD (Department of Surgical Oncology, Claudius Regaud Institute IUTC, Toulouse, France); Juliette Fontaine, MD (Department of Pathology, Lyon-Sud University Hospital, Lyon, France); Laure Fournier (Department of Radiology, G. Pompidou European Hospital, Paris, France); Johan Gagniere, MD (Department of Digestive Surgery, Estaing University Hospital, Clermont-Ferrand, France); Delphine Geffroy, MD (Department of Radiology, ICO René Gauducheau Cancer Center, Saint-Herblain, France); Laurent Ghouti, MD (Department of Digestive Surgery, Purpan University Hospital, Toulouse, France); François-Noël Gilly, MD, PhD (Department of Digestive Surgery, Lyon-Sud University Hospital, Lyon, France); Laurence Gladieff (Department of Medical Oncology, Claudius Regaud Institute IUTC, Toulouse, France); Olivier Glehen, MD, PhD (Department of Digestive Surgery, Lyon-Sud University Hospital, Lyon, France); Diane Goéré, MD, PhD. (Department of Surgical Oncology, Gustave Roussy Institute, Villejuif, France); Aymeric Guibal, MD (Department of Radiology, Hospital of Perpignan, Perpignan, France); Jean-Marc Guilloit, MD (Department of Surgical Oncology, Francois Baclesse Comprehensive Cancer Center, Caen, France); Frédéric Guyon, MD (Department of Surgical Oncology, Bergonie Institute, Bordeaux, France); Bruno Heyd, MD, PhD (Department of Digestive Surgery, Minjoz University Hospital, Besançon, France); Christine Hoeffel, MD, PhD (Department of Radiology, Robert Debré University Hospital, Reims, France). Constance Hordonneau (Department of Radiology, Montpied University Hospital, Clermont-Ferrand, France); Sylvie Isaac, MD (Department of Pathology, Lyon-Sud University Hospital, Lyon, France); Peggy Jourdan-Enfer (Department of Digestive Surgery, Lyon-Sud University Hospital, Lyon, France); Rachid Kaci, MD (Department of Pathology, Lariboisière University Hospital, Paris, France); Reza Kianmanesh (Department of Digestive Surgery, Robert Debré University Hospital, Reims, France); Catherine Labbé-Devilliers, MD (Department of Radiology, ICO René Gauducheau Cancer Center, Saint-Herblain, France); Joëlle Lacroix, MD (Department of Radiology, Francois Baclesse Comprehensive Cancer Center, Caen, France); Bernard Lelong, MD (Department of Surgical Oncology, Paoli Calmettes Institute, Marseille, France); Agnès Leroux-Broussier, MD (Department of Pathology, Lorraine Institute of Oncology, Vandoeuvre-les-Nancy, France); Yoann Lherm (Hospices Civils de Lyon, Pôle Information Médicale Evaluation Recherche, Unité de Recherche Clinique, Lyon, France); Réa Lo Dico, MD (Surgical Oncologic and Digestive Unit, Lariboisière University Hospital, Paris, France); Gérard Lorimier, MD (Department of Digestive Surgery, Angers University Hospital, Angers, France); Caroline Malhaire, MD (Department of Radiology, Curie Institute, Paris, France); Frédéric Marchal, MD, PhD (Department of Surgical Oncology, Lorraine Institute of Oncology, CRAN, Université de Lorraine, CNRS, Vandoeuvre-les-Nancy, France); Pascale Mariani, MD (Department of Surgical Oncology, Curie Institute, Paris, France); Emilie Mathiotte (Hospices Civils de Lyon, Pôle Information Médicale Evaluation Recherche, Unité de Recherche Clinique, Lyon, France); Pierre Meeus, MD (Department of Surgery, Léon Bérard Comprehensive Cancer Center, Lyon, France); Eliane Mery, MD (Department of Pathology, Claudius Regaud Institute IUTC, Toulouse, France); Simon Msika, MD, PhD (Department of Surgery, Louis Mourier University Hospital, Colombes, France); Cédric Nadeau, MD (Gynaecology and Obstetrics Ward, Mother and Child Pole, Poitiers University Hospital, University of Poitiers, Poitiers, France); Pablo Ortega-Deballon, MD, PhD (Department of Digestive Surgical Oncology, University Hospital of Dijon, Dijon, France); Guillaume Passot, MD, PhD (Department of Digestive Surgery, Lyon-Sud University Hospital, Lyon, France); Olivier Pellet, MD (INOLA, Lyon, France); Patrice Peyrat, MD (Department of Surgery, Léon Bérard Comprehensive Cancer Center, Lyon, France); Denis Pezet, MD, PhD (Department of Digestive Surgery, Estaing University Hospital, Clermont-Ferrand, France); Nicolas Pirro, MD, PhD (Department of Digestive Surgery, Timône University Hospital, Marseille, France); Marc Pocard, MD, PhD (Surgical Oncologic and Digestive Unit, Lariboisière University Hospital, Paris, France); Flora Poizat, MD (Department of Pathology, Paoli Calmettes Institute, Marseille, France); Jack Porcheron, MD, PhD (Department of Digestive Surgery, St Etienne University Hospital, St Etienne, France); Anaïs Poulet, PhD (Department of Digestive Surgery, Lyon-Sud University Hospital, Lyon, France); François Quenet, MD (Department of Surgical Oncology, Val d’Aurelle Montpellier Cancer Center, Montpellier, France); Patrick Rat, MD, PhD (Department of Digestive Surgical Oncology, University Hospital of Dijon, Dijon, France); Pierre Rousselot, MD (Department of Pathology, Francois Baclesse Comprehensive Cancer Center, Caen, France); Pascal Rousset, MD, PhD (Department of Radiology, Lyon-Sud University Hospital, Lyon, France); Hélène Senellart (Department of Medical Oncology, ICO René Gauducheau Cancer Center, Saint-Herblain, France); Martine Serrano (Department of Digestive Surgery, Lyon-Sud University Hospital, Lyon, France); Vincent Servois, MD (Department of Radiology, Curie Institute, Paris, France); Olivia Sgabura MD (Department of Surgical Oncology, Val d’Aurelle Montpellier Cancer Center, Montpellier, France); Andrea Skanjeti, MD (Department of Radiology, Lyon-Sud University Hospital, Lyon, France); Magali Svrcek, MD, PhD (Department of Pathology, Hospital Saint-Antoine AP-HP, Paris, France); Raphaël Tetreau, MD, (Department of Radiology, Val d’Aurelle Montpellier Cancer Center, Montpellier, France); Emilie Thibaudeau, MD (Department of Surgical Oncology, ICO René Gauducheau Cancer Center, Saint-Herblain, France); Yann Touchefeu (Department of Gastroenterology, Nantes University Hospital, Nantes); Jean-Jacques Tuech, MD, PhD (Department of Digestive Surgery, Charles Nicolle University Hospital, Rouen, France); Séverine Valmary-Degano, MD, PhD (Department of Pathology, Minjoz University Hospital, Besançon, France); Delphine Vaudoyer, MD (Department of Digestive Surgery, Lyon-Sud University Hospital, Lyon, France); Stéphane Velasco, MD (Department of Radiology, Poitiers University Hospital, Poitiers, France); Véronique Verriele-Beurrier, MD (Department of Pathology, ICO Paul Papin Cancer Center, Angers, France); Laurent Villeneuve (Hospices Civils de Lyon, Pôle Information Médicale Evaluation Recherche, Unité de Recherche Clinique, Lyon, France); Romuald Wernert, MD (Department of Surgical Oncology, ICO Paul Papin Cancer Center, Angers, France); Franck Zinzindohoue, MD, PhD (Department of Digestive and General Surgery, G. Pompidou European Hospital, Paris, France).

Disclosure

None declared.

Supplementary material

10434_2018_6631_MOESM1_ESM.docx (18 kb)
Supplementary material 1 (DOCX 90 kb)
10434_2018_6631_MOESM2_ESM.tiff (1.1 mb)
Supplementary material 1 (tiff 1143 kb)
10434_2018_6631_MOESM3_ESM.tiff (1.1 mb)
Supplementary material 1 (tiff 1143 kb)

References

  1. 1.
    Price B, Ware A. Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005. Crit Rev Toxicol. 2009; 39:576–588.CrossRefPubMedGoogle Scholar
  2. 2.
    Moolgavkar SH, Meza R, Turim J. Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973–2005. Cancer Causes Control. 2009; 20:935–944.CrossRefPubMedGoogle Scholar
  3. 3.
    Larson T, Melnikova N, Davis SI, et al. Incidence and descriptive epidemiology of mesothelioma in the United States, 1999–2002. Int J Occup Environ Health. 2007; 13:398-403.CrossRefPubMedGoogle Scholar
  4. 4.
    Deraco M, Baratti D, Hutanu I, et al. The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2013; 20:1093–1100.CrossRefPubMedGoogle Scholar
  5. 5.
    Sugarbaker PH, Turaga KK, Alexander HR, et al. Management of malignant peritoneal mesothelioma using cytoreductive surgery and perioperative chemotherapy. J Oncol Pract. 2016; 12:928–935.CrossRefPubMedGoogle Scholar
  6. 6.
    Hubert J, Thiboutot E, Dubé P, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal mesothelioma: preliminary results and survival analysis. Surg Oncol. 2015; 24:41–46.CrossRefPubMedGoogle Scholar
  7. 7.
    Baratti D, Kusamura S, Cabras AD, et al. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Cancer. 2013; 49:3140–3148.CrossRefPubMedGoogle Scholar
  8. 8.
    Tan GH, Cheung M, Chanyaputhipong J, et al. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma. Ann Acad Med Singapore. 2013; 42:291–296.PubMedGoogle Scholar
  9. 9.
    Mirarabshahii P, Pillai K, Chua TC, et al. Diffuse malignant peritoneal mesothelioma—an update on treatment. Cancer Treat Rev. 2012; 38:605–612.CrossRefPubMedGoogle Scholar
  10. 10.
    Magge D, Zenati MS, Austin F, et al. Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis. Ann Surg Oncol. 2014; 21:1159–1165.CrossRefPubMedGoogle Scholar
  11. 11.
    Chua TC, Yan TD, Morris DL. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: the Australian experience. J Surg Oncol. 2009; 99:109–113.CrossRefPubMedGoogle Scholar
  12. 12.
    Goslin B, Sevak S, Siripong A, et al. Outcomes of cytoreduction with hyperthermic intraperitoneal chemotherapy: our experience at a midwest community hospital. Am J Surg. 2012; 203:383–386.CrossRefPubMedGoogle Scholar
  13. 13.
    Elias D, Bedard V, Bouzid T, et al. Malignant peritoneal mesothelioma: treatment with maximal cytoreductive surgery plus intraperitoneal chemotherapy. Gastroenterol Clin Biol. 2007; 31:784–788.CrossRefPubMedGoogle Scholar
  14. 14.
    Kepenekian V, Elias D, Passot G, et al. Diffuse malignant peritoneal mesothelioma: evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study. Eur J Cancer. 2016; 65:69–79.CrossRefPubMedGoogle Scholar
  15. 15.
    Cao S, Jin S, Cao J, et al. Advances in malignant peritoneal mesothelioma. Int J Colorectal Dis. 2015; 30:1–10.CrossRefPubMedGoogle Scholar
  16. 16.
    Acherman YI, Welch LS, Bromley CM, et al. Clinical presentation of peritoneal mesothelioma. Tumori. 2003; 89:269–273.CrossRefPubMedGoogle Scholar
  17. 17.
    Sugarbaker PH, Acherman YI, Gonzalez-Moreno S, et al. Diagnosis and treatment of peritoneal mesothelioma: The Washington Cancer Institute experience. Semin Oncol. 2002; 29:51–61.CrossRefPubMedGoogle Scholar
  18. 18.
    Yan TD, Deraco M, Elias D, et al. A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database*. Cancer. 2011; 117:1855–1863.CrossRefPubMedGoogle Scholar
  19. 19.
    Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009; 27:6237–6242.CrossRefPubMedGoogle Scholar
  20. 20.
    Alexander HR, Bartlett DL, Pingpank JF, et al. Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery. 2013; 153:779–786.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Yan TD, Welch L, Black D, et al. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol. 2007; 18:827–834.CrossRefPubMedGoogle Scholar
  22. 22.
    Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003; 21:4560–4567.CrossRefPubMedGoogle Scholar
  23. 23.
    Nonaka D, Kusamura S, Baratti D, et al. Diffuse malignant mesothelioma of the peritoneum: a clinicopathological study of 35 patients treated locoregionally at a single institution. Cancer. 2005; 104:2181–2188.CrossRefPubMedGoogle Scholar
  24. 24.
    Yan TD, Brun EA, Cerruto CA, et al. Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma. Ann Surg Oncol. 2007; 14:41–49.CrossRefPubMedGoogle Scholar
  25. 25.
    Leinwand JC, Zhao B, Guo X, et al. Quantitative X-ray computed tomography peritoneography in malignant peritoneal mesothelioma patients receiving intraperitoneal chemotherapy. Ann Surg Oncol. 2013; 20:S553–559.CrossRefPubMedGoogle Scholar
  26. 26.
    Alexander HR, Burke AP. Diagnosis and management of patients with malignant peritoneal mesothelioma. J Gastrointest Oncol. 2016; 7:79–86.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Sugarbaker PH, Van der Speeten K. Surgical technology and pharmacology of hyperthermic perioperative chemotherapy. J Gastrointest Oncol. 2016; 7:29–44.PubMedPubMedCentralGoogle Scholar
  28. 28.
    The National Cancer Institute’s Common Terminology Criteria for Adverse Events v3.0update. Available at: http://ctep.cancer.gov/protocolDevelopment/electronicapplications/docs/ctcaev3.pdf.
  29. 29.
    Cotte E, Passot G, Gilly FN, et al. Selection of patients and staging of peritoneal surface malignancies. World J Gastrointest Oncol. 2010; 2:31–35.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996; 82:359–374.CrossRefPubMedGoogle Scholar
  31. 31.
    Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995; 221:29–42.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Landrum LM, Java J, Mathews CA, et al. Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol. 2013; 130:12–18.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Shimada S, Kuramoto M, Marutsuka T, et al. Adopting extensive intra-operative peritoneal lavage (EIPL) as the standard prophylactic strategy for peritoneal recurrence. Rev Recent Clin Trials. 2011; 6:266–270.CrossRefPubMedGoogle Scholar
  34. 34.
    Harrison LE, Tiesi G, Razavi R, et al. A phase I trial of thermal sensitization using induced oxidative stress in the context of HIPEC. Ann Surg Oncol. 2013; 20:1843–1850.CrossRefPubMedGoogle Scholar
  35. 35.
    Lang-Lazdunski L, Bille A, Papa S, et al. Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine, prophylactic radiotherapy, and systemic chemotherapy in patients with malignant pleural mesothelioma: a 10-year experience. J Thorac Cardiovasc Surg. 2015; 149:558–565.CrossRefPubMedGoogle Scholar
  36. 36.
    Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009; 250:187–196.CrossRefPubMedGoogle Scholar
  37. 37.
    Helm JH, Miura JT, Glenn JA, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol. 2015; 22:1686–1693.CrossRefPubMedGoogle Scholar
  38. 38.
    Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med. 1960; 17:260–271.PubMedPubMedCentralGoogle Scholar
  39. 39.
    Simon GR, Verschraegen CF, Jänne PA, et al. Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. J Clin Oncol. 2008; 26:3567–3572.CrossRefPubMedGoogle Scholar
  40. 40.
    Jänne PA, Wozniak AJ, Belani CP, et al. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer. 2005; 7:40–46.CrossRefPubMedGoogle Scholar
  41. 41.
    Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003; 21:2636–2644.CrossRefPubMedGoogle Scholar
  42. 42.
    Carteni G, Manegold C, Garcia GM, et al. Malignant peritoneal mesothelioma-results from the international expanded access program using pemetrexed alone or in combination with a platinum agent. Lung Cancer. 2009; 64:211–218.CrossRefPubMedGoogle Scholar
  43. 43.
    Garcia-Carbonero R, Paz-Ares L. Systemic chemotherapy in the management of malignant peritoneal mesothelioma. Eur J Surg Oncol. 2006; 32:676–681.CrossRefPubMedGoogle Scholar
  44. 44.
    Cameron RB, Hou D. Intraoperative hyperthermic chemotherapy perfusion for malignant pleural mesothelioma: an in vitro evaluation. J Thorac Cardiovasc Surg. 2013; 145:496–504.CrossRefPubMedGoogle Scholar
  45. 45.
    Le DT, Deavers M, Hunt K, et al. Cisplatin and irinotecan (CPT-11) for peritoneal mesothelioma. Cancer Invest. 2003; 21:682–689.CrossRefPubMedGoogle Scholar
  46. 46.
    Sugarbaker PH, Chang D. Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival. Eur J Surg Oncol. 2017; 43:1228–1235.CrossRefPubMedGoogle Scholar
  47. 47.
    Quenet F, Goere D, Mehta SS et al. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis. Ann Surg. 2011; 254:294–301.CrossRefPubMedGoogle Scholar
  48. 48.
    Blackham AU, Shen P, Stewart JH, et al. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for malignant peritoneal mesothelioma: mitomycin versus cisplatin. Ann Surg Oncol. 2010; 17:2720–2727.CrossRefPubMedGoogle Scholar
  49. 49.
    Hazarika M, White RM, Johnson JR, et al. FDA drug approval summaries: pemetrexed (Alimta). The Oncologist. 2004; 9:482–488.CrossRefPubMedGoogle Scholar
  50. 50.
    Badrudin D, Perrault-Mercier C, Bouchard-Fortier A, et al. Pharmacokinetics and the effect of heat on intraperitoneal pemetrexed using a murine model. Surg Oncol. 2016; 25:435–440.CrossRefPubMedGoogle Scholar
  51. 51.
    Pestieau SR, Stuart OA, Sugarbaker PH. Multi-targeted antifolate (MTA): pharmacokinetics of intraperitoneal administration in a rat model. Eur J Surg Oncol. 2000; 26:696–700.CrossRefPubMedGoogle Scholar
  52. 52.
    Gouy S, Belghiti J, Uzan C, et al. Accuracy and reproducibility of the peritoneal cancer index in advanced ovarian cancer during laparoscopy and laparotomy. Int J Gynecol Cancer. 2013; 23:1699–1703.CrossRefPubMedGoogle Scholar
  53. 53.
    Husain AN, Colby TV, Ordóñez NG, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2009; 133:1317–1331.PubMedGoogle Scholar
  54. 54.
    Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010; 28:63–68.CrossRefPubMedGoogle Scholar
  55. 55.
    Portilla AG, Shigeki K, Dario B, et al. The intraoperative staging systems in the management of peritoneal surface malignancy. J Surg Oncol. 2008; 98:228–231.CrossRefPubMedGoogle Scholar
  56. 56.
    Elias D, Souadka A, Fayard F, et al. Variation in the peritoneal cancer index scores between surgeons and according to when they are determined (before or after cytoreductive surgery). Eur J Surg Oncol. 2012; 38:503–508.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  • Brice Malgras
    • 1
    • 2
  • Etienne Gayat
    • 3
  • Olivier Aoun
    • 4
  • Réa Lo Dico
    • 1
  • Clarisse Eveno
    • 1
  • Karine Pautrat
    • 1
  • Jean-Baptiste Delhorme
    • 5
  • Guillaume Passot
    • 6
  • Frédéric Marchal
    • 7
  • Olivia Sgarbura
    • 8
  • Gwenael Ferron
    • 9
  • Diane Goéré
    • 10
  • Thierry Andre
    • 11
  • Marc Pocard
    • 1
  • on behalf of the RENAPE Network
  1. 1.Department of Digestive and Oncologic Surgery, Hôpital Lariboisière – AP-HPUniversité Paris Diderot-Paris 7 and INSERM U 965ParisFrance
  2. 2.Department of Digestive SurgeryBegin Military Teaching HospitalSaint MandéFrance
  3. 3.Department of Anesthesiology and Critical Care Medicine, Hôpital Lariboisière – AP-HPUniversité Paris Diderot-Paris 7 and INSERM U 942ParisFrance
  4. 4.5th Armed Forces Medical CenterStrasbourgFrance
  5. 5.Department of General and Digestive Surgery, Hautepierre HospitalStrasbourg University HospitalStrasbourgFrance
  6. 6.Department of General and Oncological Surgery, Centre Hospitalier Lyon-SudHospices Civils de LyonPierre-BéniteFrance
  7. 7.Department of Surgical Oncology, Institut de cancérologie de Lorraine, CRAN, UMR 7039Université de Lorraine, CNRSVandoeuvre-lès-NancyFrance
  8. 8.Department of Surgical OncologyMontpellier Cancer CenterMontpellierFrance
  9. 9.Department of Surgical OncologyClaudius Regaud InsituteToulouseFrance
  10. 10.Department of Surgical OncologyGustave Roussy Cancer CampusVillejuif CedexFrance
  11. 11.Department of Medical OncologyHôpital Saint AntoineParisFrance

Personalised recommendations

Cite article

Buy options